Study of Genes and the Environment in Patients With Prostate Cancer Residing in the East Anglia, Trent, or West Midlands Regions of the United Kingdom

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This study is looking at genetic susceptibility and the interactions between genes and the environment in patients with prostate cancer.

Detailed Description
-----------------
OBJECTIVES: To obtain epidemiological information and biological material on a population-based series of prostate cancer cases. To identify novel cancer susceptibility genes by comparison of genotype frequencies in cases with the corresponding frequencies in large control series. To estimate the age and sex-specific risks associated with variants in predisposition genes. To evaluate interactions between polymorphisms in predisposition genes and potential lifestyle risk factors. OUTLINE: This is a multicenter study. Patients complete a detailed epidemiological questionnaire, including information on education, occupation, smoking habits, alcohol consumption, height, weight, family history of cancer, and past medical history. Blood samples are collected from patients. DNA is extracted from these blood samples and from samples collected from cancer-free control participants in MREC-SEARCH-CONTROL as well as from additional controls through the European Prospective Investigation of Cancer (EPIC) study (a population based study of diet and health based in Norfolk, East Anglia). DNA samples are analyzed for polymorphisms of low penetrance cancer susceptibility genes. In addition to the prostate cancer patients recruited for this study, patients with breast, ovarian, endometrial, colorectal, bladder, kidney, pancreatic, brain and esophageal cancer, malignant melanoma, and lymphoma cancer are recruited in the following related clinical trials: MREC-SEARCH-BREAST, MREC-SEARCH-OVARIAN, MREC-SEARCH-ENDOMETRIAL, MREC-SEARCH-COLORECTAL, and MREC-SEARCH-CANCER.

Official Title
-----------------
A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Prostate Cancer in East Anglia, Trent and West Midlands

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Genetic: polymorphism analysis
* Other: laboratory biomarker analysis
* Other: questionnaire administration


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Diagnosis of prostate cancer within the past 5 years Identified through the cancer registry serving any of the following geographic regions of the United Kingdom: East Anglia Trent West Midlands PATIENT CHARACTERISTICS: Identified by the patient's general practitioner as fit to contact for this study No serious mental illness or retardation PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: polymorphism analysis|nan|
|Other: laboratory biomarker analysis|nan|
|Other: questionnaire administration|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acquisition of epidemiological information and biological material |  |  | 
| Identification of novel cancer susceptibility genes |  |  | 
| Estimation of the age and sex-specific risks associated with variants in predisposition genes |  |  | 
| Evaluation interactions between polymorphisms in predisposition genes and potential lifestyle risk factors |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
prostate cancer